Sinuvac (SVA) Reports Swine Flu Success
Aug 18th, 2009 | By J. Christoph Amberger | Category: Stock Market InvestingThe unexpected absence of the Chinese fencing coach can only be due to one thing: Sinuvac’s (AMEX:SVA) reported a breakthrough with their new anti- H1N1 swine flu vaccine!
When I asked Bin Lu, my Chinese fencing coach, earlier this summer if he’d be embarking on his annual pilgrimage to China this summer, he seemed dubious.
“Afraid they put me in quarantine,” he said. “Swine flu.”
Indeed, his hesitation seemed reasonable: A volleyball team from my son’s high school spent most of their trip to China locked up in a Beijing hotel. And the Kawasaki delegation of Japanese scouts that part of our Boy Scout troop had been preparing to host for the better part of a year canceled their visit for fear of the porcine virus.
So I knew I was facing a turning point last night when I heard that Coach Bin had left for Shanghai, sticking me with a bunch of kids signed up for fencing lessons on Thursday night.
The news today confirmed my suspicions:
Sinovac Biotech Ltd. (AMEX:SVA) has developed a swine flu vaccine that is now safe. According to reports, it protects people after a single shot.
Inoculation has caused no severe adverse reactions in the 1,614 volunteers who received it, according to the company.
“The results are the first reported anywhere in the world on a vaccine to fight the new H1N1 strain that’s sparked the first influenza pandemic in 41 years,” said the company.
With U.S. vaccine manufacturers already behind schedule producing the amounts of vaccine ordered up by the U.S. government, that means Sinovac has the inside track on the world H1N1 vaccine market.
The stock rose over 10% today. Keep an eye on the stock… if U.S. manufacturers are not catching up, this one may be a medium-term winner.
Source: Sinuvac (SVA) Reports Swine Flu Success
Advertisement
42% on Nymox Pharmaceutical Corp....
23% on Emergent BioSolutions Inc....
38% on the first half of our position in a U.S. refiner...
26.68% on Synta Pharmaceuticals...
How's your favorite financial newsletter working out for you?
Hot Stock Confidential = Damn Good Stocks.
Learn more...
Amberger began his career as a freelance contributor to Agora publications before emigrating from Germany to the United States in 1989, when he joined the editorial board of Taipan. In 1991, he took over as managing editor for the publication and assumed responsibility as group publisher four years later. In 2007 Christoph left Taipan and founded TodaysFinancialNews.com along with its premium publications: the highly successful stock Hot Stock Confidential, the options research service TFN Strategic Trader and, most recently, Penny Stock Confidential. In November of 2009, he welcomed Contrarian Profits to the Today's Financial News network.
Sinovac Biotech Ltd. announced the positive top line results from the completed clinical trial for its internally developed H1N1 vaccine. The clinical data unblinding conference was held in Beijing on the afternoon of August 17, 2009. The analysis of the clinical trial results showed that the H1N1 vaccine developed by Sinovac induces good immunogenicity after one dose. The seropositive rate, seroconvertive rate and GMT increasing multiple have reached the international criteria for vaccines, which indicates that Sinovac’s H1N1 vaccine has good immunogenicity and offers protection. After receiving one shot of the vaccine, none of the volunteers participating in Sinovac’s clinical trials exhibited any signs of severe adverse reactions. The adverse events were all mild and transient, with pain at the site of injection as common symptom. The total adverse event rate is similar to the seasonal influenza vaccine. These results demonstrated that the H1N1 vaccine has a good safety profile.